Short answer
RHYTHM PHARMACEUTICALS, INC. (RYTM) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). August 4, 2026 filing references two press releases and an investor presentation covering fiscal-year 2026 results.
RHYTHM PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- August 4, 2026 filing references two press releases and an investor presentation covering fiscal-year 2026 results
- Financial and operating details reside in Exhibits 99.1–99.3, requiring review for revenue, earnings, guidance, and pipeline updates
- CFO Hunter C. Smith signed the report on August 4, 2026
Item 7.01 · Regulation FD Disclosure
- Preliminary Phase 2 RM-718 data in acquired hypothalamic obesity, an obesity-related indication
- Ongoing trial update; findings remain preliminary and may change as enrollment and follow-up continue
- Press release and investor presentation contain the disclosed efficacy and safety data
Item 8.01 · Other Events
- Preliminary Phase 2 data: RM-718 reduced mean BMI 11.6% at 16 weeks in acquired hypothalamic obesity patients
- Efficacy comparable to bivamelagon and setmelanotide benchmarks, each showing 10.1% mean BMI reduction
- Safety generally manageable, with injection-site reactions, nausea, and vomiting most common
- Two mild injection-site hyperpigmentation cases; no generalized hyperpigmentation observed
- Two patients discontinued for adverse events, while eight remained on active treatment as of July 16, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RHYTHM PHARMACEUTICALS, INC. 8-K filings
Get the next RYTM 8-K as it lands
Follow RYTM for push alerts, or ask the research agent what this filing means.